Related Experiment Video
Updated: Jul 7, 2026
10:36
In Vitro Imaging and Quantification of the Drug Targeting Efficiency of Fluorescently Labeled GnRH Analogues
Published on: March 21, 2017
Comparative Positioning of Orforglipron Among Selected GLP-1 Receptor Agonist Benchmarks: A Narrative Review
José Castro-Gamboa1, Jeaustin Mora-Jiménez2, Sebastián Arguedas-Chacón3
1Pharmacy, Universidad de Costa Rica, San José, CRI.
Cureus
|July 6, 2026
Summary
Orforglipron, a novel oral GLP-1 receptor agonist, shows promise for type 2 diabetes and obesity. While offering advantages like once-daily dosing, more long-term data is needed to establish its therapeutic role compared to existing treatments.
Area of Science:
- Pharmacology
- Endocrinology
- Drug Development
Background:
- Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are critical for managing type 2 diabetes and obesity.
- Orforglipron represents a new class of oral, nonpeptide, small-molecule GLP-1 RAs.
Purpose of the Study:
- To evaluate orforglipron's comparative position among existing GLP-1 RAs.
- To integrate structural, pharmacological, clinical, and practical evidence for positioning orforglipron.
Main Methods:
- A narrative literature review was conducted across major databases (PubMed/MEDLINE, Embase, Scopus, Web of Science, ClinicalTrials).
- Included analysis of prescribing information and citation tracking.
- Comparative evidence was synthesized across molecular structure, pharmacology, clinical data, and administration.
Main Results:
- Orforglipron's nonpeptide small-molecule structure and once-daily oral dosing are key features.
- Direct comparative data exists against dulaglutide and oral semaglutide.
- Fewer food-related administration constraints were noted compared to oral semaglutide, though indirect comparisons have limitations.
Conclusions:
- Orforglipron is an emerging oral GLP-1 RA with potential, but not yet a proven superior replacement for current therapies.
- Further long-term data on cardiovascular outcomes, renal effects, safety, adherence, and real-world effectiveness are required.
- Its definitive place in therapy requires additional comprehensive studies.
Related Concept Videos
01:24Glucagon-like Receptor Agonists
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
01:06Oral Hypoglycemic Agents: Glinides
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively manages...
01:26Oral Hypoglycemic Agents: Biguanides and Glitazones
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood glucose levels...
01:23Dipeptidyl Peptidase 4 Inhibitors
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a significant...
01:19Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are typically...
Acarbose and miglitol are typically...
01:17Oral Hypoglycemic Agents: Sulfonylureas
Sulfonylureas are oral hypoglycemic agents utilized in treating type 2 diabetes. They are characterized by their unique sulfonylurea chemical structure. The family of sulfonylureas is divided into generations. First-generation sulfonylureas, including tolbutamide (Orinase), chlorpropamide (Diabinese), and tolazamide (Tolinase), trigger insulin release from pancreatic β cells and enhance peripheral tissues' insulin sensitivity. The second-generation members, such as glipizide (Glucotrol),...